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All-in-one adeno-associated virus delivery
and genome editing by Neisseria
meningitidis Cas9 in vivo
Raed Ibraheim1, Chun-Qing Song1, Aamir Mir1, Nadia Amrani1, Wen Xue1,2 and Erik J. Sontheimer1,2*
Abstract
Background: Clustered, regularly interspaced, short palindromic repeats (CRISPR) and CRISPR-associated proteins
(Cas) have recently opened a new avenue for gene therapy. Cas9 nuclease guided by a single-guide RNA (sgRNA)
has been extensively used for genome editing. Currently, three Cas9 orthologs have been adapted for in vivo genome
engineering applications: Streptococcus pyogenes Cas9 (SpyCas9), Staphylococcus aureus Cas9 (SauCas9), and Campylobacter
jejuni (CjeCas9). However, additional in vivo editing platforms are needed, in part to enable a greater range of sequences to
be accessed via viral vectors, especially those in which Cas9 and sgRNA are combined into a single vector genome.
Results: Here, we present in vivo editing using Neisseria meningitidis Cas9 (NmeCas9). NmeCas9 is compact, edits with high
accuracy, and possesses a distinct protospacer adjacent motif (PAM), making it an excellent candidate for safe gene therapy
applications. We find that NmeCas9 can be used to target the Pcsk9 and Hpd genes in mice. Using tail-vein hydrodynamic-
based delivery of NmeCas9 plasmid to target the Hpd gene, we successfully reprogram the tyrosine degradation pathway
in Hereditary Tyrosinemia Type I mice. More importantly, we deliver NmeCas9 with its sgRNA in a single recombinant
adeno-associated vector (rAAV) to target Pcsk9, resulting in lower cholesterol levels in mice. This all-in-one vector yielded
> 35% gene modification after two weeks of vector administration, with minimal off-target cleavage in vivo.
Conclusions: Our findings indicate that NmeCas9 can enable the editing of disease-causing loci in vivo, expanding the
targeting scope of RNA-guided nucleases.
Keywords: CRISPR, All-in-one rAAV, Genome editing, NmeCas9
Background
A major advance in the field of gene therapy has been
the introduction of Cas9 nuclease-enabled genome edit-
ing [1]. Clustered, regularly interspaced, short palin-
dromic repeats (CRISPR) loci specify an adaptive
immune pathway that evolved in bacteria and archaea to
defend against mobile genetic elements (MGEs) [2, 3].
The effector complex in type II CRISPR systems in-
cludes the Cas9 nuclease, which is guided by a CRISPR
RNA (crRNA) and a trans-activating RNA (tracrRNA).
These dual RNAs can be fused to form a single-guide
RNA (sgRNA) [4]. Each crRNA contains a unique “spa-
cer” sequence that can be programmed to cleave a DNA
segment of interest. Cas9 scans DNA for a specific pro-
tospacer adjacent motif (PAM), opens the duplex to
form an RNA-DNA hybrid between the guide and the
spacer, and introduces a double-strand break (DSB) in
the DNA target [1, 3]. Cas9 and sgRNA have been
adapted to enable genome editing in cultured cells fol-
lowing various modes of delivery including plasmid and
RNA transfections, viral transduction, and ribonucleo-
protein (RNP) electroporation. Precise and efficient in
vivo editing is more difficult to achieve, largely due to
the difficulties inherent in delivery.
Several methods have been developed to deliver Cas9 in
vivo including viral and non-viral methods [5]. These in-
clude the use of gold and lipid nanoparticles to deliver
Cas9 in RNP or RNA form in mice. However, these
methods present challenges for routine use including cost
and tissue distribution [6–8]. One of the more intriguing
gene delivery vehicles that has emerged in recent years is
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recombinant adeno-associated virus (rAAV). This vector
possesses several attributes that benefit gene therapy appli-
cations, including lack of pathogenicity and replication as
well as an ability to infect dividing and non-dividing cells
[9]. In addition, rAAV is also capable of infecting a wide
range of cells and maintain sustained expression [10, 11].
Compared to other viral vectors, rAAV persists in concate-
meric, episomal forms, while eliciting mild immune re-
sponses [12–14]. The usefulness of rAAV-based delivery
for gene therapy is reflected in the number of clinical trials
involving rAAV [15]. One of the most exciting advance-
ments for rAAV gene therapy field has been the FDA’s re-
cent market approval of a therapy for RPE65-mediated
inherited retinal disease (IRD), the first of its kind in the
United States [16].
More recently, several groups have focused their ef-
forts on using this tool for in vivo delivery of Cas9
orthologs [17–20]. The majority of Cas9 genome editing
efforts have been focused on the widely used type II-A
ortholog from Streptococcus pyogenes, SpyCas9. Al-
though it exhibits consistently robust genome-editing
activity, considerable effort has been required to over-
come off-target editing activities of wild-type SpyCas9
[21–23] [Amrani et al., manuscript in revision (https://
www.biorxiv.org/content/early/2018/05/09/172650)].
Furthermore, its large size (1368 amino acids, 4.10 kb) re-
stricts its delivery with its guide in a single virion with po-
tent vectors such as rAAV [24]. Split SpyCas9 constructs
(expressed from separate viruses) have been employed
[19], though activity is sometimes compromised [25–27].
Dual-rAAV delivery of SpyCas9 and sgRNA can be
achieved [28], but it requires the usage of highly mini-
mized promoters that limit expression and tissue specifi-
city. Furthermore, dual rAAV formats carry significant
costs as well as limitations in co-transduction.
Alternatively, compact Cas9 orthologs can be packaged
in all-in-one rAAV vectors. Type II-A Staphylococcus
aureus (SauCas9) (1053 amino acids, 3.16 kb) and type
II-C Campylobacter jejuni Cas9 (CjeCas9) (984 amino
acids, 2.95 kb) have been deployed successfully via rAAV
in mice [18, 20]. However, unlike the highly abundant
NGG SpyCas9 PAM, these Cas9 nucleases have more re-
strictive PAM requirements (for SauCas9, 5’-NNGRRT-3′;
for CjeCas9, 5’-N4RYAC [29]. Furthermore, off-target edit-
ing by SauCas9 is not unusual [18, 30]. For these reasons,
many genomic sites of interest cannot be targeted by
all-in-one rAAV delivery of the Cas9 genome editing ma-
chinery and additional capabilities and PAM specificities
are therefore needed.
We and others have reported genome editing in mam-
malian cells by the type II-C Cas9 from Neisseria menin-
gitidis strain 8013 (NmeCas9) [31–33] (Amrani et al.,
manuscript in revision). NmeCas9 is small (1082 amino
acids, 3.16 kb), targets PAMs (N4GAYT >N4GYTT/
N4GAYA/N4GTCT) that are distinct from those of the
other compact Cas9 orthologs described above, and is
intrinsically resistant to off-targeting [32] (Amrani et al.,
manuscript in revision). Additionally, NmeCas9 can be
subjected to off-switch control by anti-CRISPR proteins
[34], which could facilitate spatial and temporal control
over NmeCas9 activity in vivo and ex vivo.
In this study, we report the in vivo delivery of Nme-
Cas9 and its guide by a single expression cassette that is
sufficiently small for all-in-one rAAV vectors. Two
disease genes were targeted separately to highlight the
therapeutic potential of NmeCas9: the Hpd gene in a
hereditary tyrosinemia type I (HTI) mouse model
(Fahneo); and the Pcsk9 gene in C57Bl/6 mice. Hpd
encodes the 4-hydroxyphenylpyruvate dioxygenase en-
zyme in the tyrosine metabolism pathway and disrupting
Hpd can lead to a decrease in the accumulation of toxic
fumarylacetoacetate in tyrosinemia models [35]. Separ-
ately, Pcsk9 encodes proprotein convertase subtilisin/kexin
type 9 (PCSK9), an antagonist of the low-density lipopro-
tein (LDL) receptor [36, 37]. When PCSK9 is knocked out,
more LDL receptors are available at the surface of hepato-
cytes to allow cholesterol binding and recycling towards
the lysosomes for degradation [38, 39]. The alleviation of
tyrosinemia symptoms upon Hpd disruption, as well as the
reduced serum cholesterol levels that result from Pcsk9
disruption, provide convenient readouts and benchmarks
for genome editing activity [18, 35]. We used these systems
to validate all-in-one rAAV delivery of NmeCas9 as an
effective in vivo genome editing platform in mammals.
Results
Efficient genome editing using all-in-one AAV-sgRNA-
hNmeCas9 plasmid in cells and in vivo by hydrodynamic
injection
Recently, we have shown that the relatively compact Nme-
Cas9 is active in genome editing in a range of cell types
(Amrani et al., manuscript in revision). To exploit the small
size of this Cas9 ortholog, we generated an all-in-one AAV
construct with human-codon-optimized NmeCas9 under
the expression of the mouse U1a promoter and with its
sgRNA driven by the U6 promoter (Fig. 1a).
Two sites in the mouse genome were selected initially
to test the nuclease activity of NmeCas9 in vivo: the
Rosa26 “safe-harbor” gene (targeted by sgRosa26); and the
proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene
(targeted by sgPcsk9), a common therapeutic target for
lowering circulating cholesterol and reducing the risk of
cardiovascular disease (Fig. 1b). Genome-wide off-target
predictions for these guides were determined computa-
tionally using the Bioconductor package CRISPRseek 1.9.1
[40] with N4GN3 PAMs and up to six mismatches. Many
N4GN3 PAMS are inactive, so these search parameters are
nearly certain to cast a wider net than the true off-target
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profile. Despite the expansive nature of the search, our
analyses revealed no off-target sites with fewer than four
mismatches in the mouse genome (Additional file 1:
Figure S1). On-target editing efficiencies at these target
sites were evaluated in mouse Hepa1–6 hepatoma cells by
plasmid transfections and indel quantification was per-
formed by sequence trace decomposition using the Track-
ing of Indels by Decomposition (TIDE) web tool [41]. We
found > 25% indel values for the selected guides, the ma-
jority of which were deletions (Fig. 1c).
To evaluate the preliminary efficacy of the constructed
all-in-one AAV-sgRNA-hNmeCas9 vector, endotoxin-free
sgPcsk9 plasmid was hydrodynamically administered into
the C57Bl/6 mice via tail-vein injection. This method can
deliver plasmid DNA to ~ 40% of hepatocytes for transient
expression [42]. Indel analyses by TIDE using DNA ex-
tracted from liver tissues revealed 5–9% indels 10 days
after vector administration (Fig. 1d), comparable to the
editing efficiencies obtained with analogous tests of Spy-
Cas9 [43]. These results suggested that NmeCas9 is cap-
able of editing liver cells in vivo.
Knockout of 4-Hydroxyphenylpyruvate dioxygenase
rescues the lethal phenotypes of hereditary Tyrosinemia
type I mice
Hereditary Tyrosinemia type I (HT-I) is a fatal genetic
disease caused by autosomal recessive mutations in the
Fah gene, which codes for the fumarylacetoacetate hy-
droxylase (FAH) enzyme. Patients with diminished FAH
have a disrupted tyrosine catabolic pathway, leading to
the accumulation of toxic fumarylacetoacetate and succi-
nyl acetoacetate, causing liver and kidney damage [44].
Over the past two decades, the disease has been controlled
by 2-(2-Nitro-4-trifluoromethylbenzoyl) -1,3- cyclohexa-
nedione (NTBC), which inhibits 4-hydroxyphenylpyruvate
dioxygenase upstream in the tyrosine degradation path-
way, thus preventing the accumulation of the toxic metab-
olites [45]. However, this treatment requires lifelong
management of diet and medication and may eventually
require liver transplantation [46].
Several gene therapy strategies have been tested to correct
the defective Fah gene using site-directed mutagenesis [47]
or homology-directed repair by CRISPR-Cas9 [47–49]. It
has been reported that successful modification of only 1/
10,000 of hepatocytes in the liver is sufficient to rescue the
phenotypes of Fahmut/mut mice. Recently, a metabolic path-
way reprogramming approach has been suggested in which
the function of the hydroxyphenylpyruvate dioxygenase
(HPD) enzyme was disrupted by the deletion of exons 3 and
4 of the Hpd gene in the liver [35]. This provides us with a
context in which to test the efficacy of NmeCas9 editing, by
targeting Hpd and assessing rescue of the disease phenotype
in Fah mutant mice [50]. For this purpose, we screened and
identified two target sites (one each in exon 8 [sgHpd1] and
exon 11 [sgHpd2]) within the open reading frame of Hpd
(Fig. 2a). These guides induced average indel efficiencies of
10.8% and 9.1%, respectively, by plasmid transfections in
Hepa1–6 cells (Additional file 1: Figure S2).
Fig. 1 Validation of an all-in-one AAV-sgRNA-hNmeCas9 construct. a Schematic representation of a single rAAV vector expressing human-codon-
optimized NmeCas9 and its sgRNA. The backbone is flanked by AAV inverted terminal repeats (ITR). The poly(a) signal is from rabbit beta-globin
(BGH). b Schematic diagram of the Pcsk9 (top) and Rosa26 (bottom) mouse genes. Red bars represent exons. Zoomed-in views show the protospacer
sequence (red) whereas the NmeCas9 PAM sequence is highlighted in green. Double-stranded break location sites are denoted (black arrowheads).
c Stacked histogram showing the percentage distribution of insertions-deletions (indels) obtained by TIDE after AAV-sgRNA-hNmeCas9
plasmid transfections in Hepa1–6 cells targeting Pcsk9 (sgPcsk9) and Rosa26 (sgRosa26) genes. Data are presented as mean values ± SD
from three biological replicates. d Stacked histogram showing the percentage distribution of indels at Pcsk9 in the liver of C57Bl/6 mice
obtained by TIDE after hydrodynamic injection of AAV-sgRNA-hNmeCas9 plasmid
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Three groups of mice were treated by hydrodynamic
injection with either phosphate-buffered saline (PBS) or
with one of the two sgHpd1 and sgHpd2 all-in-one
AAV-sgRNA-hNmeCas9 plasmids. One mouse in the
sgHpd1 group and two in the sgHpd2 group were ex-
cluded from the follow-up study due to failed tail-vein
injections. Mice were taken off NTBC-containing water
seven days after injections and their weight was moni-
tored for 43 days post injection (Fig. 2b). Mice injected
with PBS suffered severe weight loss (a hallmark of
HT-I) and were sacrificed after losing 20% of their body
weight (Fig. 2c). Overall, all sgHpd1 and sgHpd2 mice
successfully maintained their body weight for 43 days
overall and for at least 21 days without NTBC (Fig. 2c).
NTBC treatment had to be resumed for 2–3 days for
two mice that received sgHpd1 and one that received
sgHpd2 to allow them to regain body weight during the
third week after plasmid injection, perhaps due to low
initial editing efficiencies, liver injury due to hydro-
dynamic injection, or both. Conversely, all other sgHpd1
and sgHpd2 treated mice achieved indels with frequen-
cies in the range of 35–60% (Fig. 2d). This level of gene
inactivation likely reflects not only the initial editing
events but also the competitive expansion of edited cell
lineages (after NTBC withdrawal) at the expense of their
unedited counterparts [46, 47, 49]. Liver histology re-
vealed that liver damage is substantially less severe in
the sgHpd1- and sgHpd2-treated mice compared to
Fahmut/mut mice injected with PBS, as indicated by
the smaller numbers of multinucleated hepatocytes com-
pared to PBS-injected mice (Additional file 1: Figure S3).
In vivo genome editing by NmeCas9 delivered by a rAAV
vector
Although plasmid hydrodynamic injections can generate
indels, therapeutic development will require less invasive
delivery strategies, such as rAAV. To this end, all-in-one
AAV-sgRNA-hNmeCas9 plasmids were packaged in
hepatocyte-tropic AAV8 capsids to target Pcsk9 (sgPcsk9)
and Rosa26 (sgRosa26) (Fig. 1b) [51, 52]. Pcsk9 and Rosa26
Fig. 2 NmeCas9-mediated knockout of Hpd rescues the lethal phenotype in Hereditary Tyrosinemia Type I Mice. a Schematic diagram of the Hpd
mouse gene. Red bars represent exons. Zoomed-in views show the protospacer sequences (red) for targeting exon 8 (sgHpd1) and exon 11
(sgHpd2). NmeCas9 PAM sequences are in green and double-stranded break locations are indicated (black arrowheads). b Experimental design.
Three groups of Hereditary Tyrosinemia Type I Fah−/− mice are injected with PBS or all-in-one AAV-sgRNA-hNmeCas9 plasmids sgHpd1 or sgHpd2.
c Weight of mice hydrodynamically injected with PBS (green), AAV-sgRNA-hNmeCas9 plasmid sgHpd1 targeting Hpd exon 8 (red) or sgHpd2-
targeting Hpd exon 11 (blue) were monitored after NTBC withdrawal. Error bars represent three mice for PBS and sgHpd1 groups and two mice
for the sgHpd2 group. Data are presented as mean ± SD. d Stacked histogram showing the percentage distribution of indels at Hpd in liver of
Fah−/− mice obtained by TIDE after hydrodynamic injection of PBS or sgHpd1 and sgHpd2 plasmids. Livers were harvested at the end of NTBC
withdrawal (day 43)
Ibraheim et al. Genome Biology  (2018) 19:137 Page 4 of 11
were used in part to enable NmeCas9 AAV delivery to be
benchmarked with that of other Cas9 orthologs delivered
similarly and targeted to the same loci [18]. Vectors were
administered into C57BL/6 mice via tail vein (Fig. 3a). We
monitored cholesterol level in the serum and measured
PCSK9 protein and indel frequencies in the liver tissues
25 and 50 days post injection.
Using a colorimetric endpoint assay, we determined
that the circulating serum cholesterol level in the
sgPcsk9 mice decreased significantly (p < 0.001) com-
pared to the PBS and sgRosa26 mice at 25 and 50 days
post injection (Fig. 3b). Targeted deep-sequencing ana-
lyses at Pcsk9 and Rosa26 target sites revealed very effi-
cient indels of 35% and 55%, respectively, at 50 days
post vector administration (Fig. 3c). Additionally, one
mouse of each group was euthanized at 14 days post in-
jection and revealed on-target indel efficiencies of 37%
and 46% at Pcsk9 and Rosa26, respectively (Fig. 3c). As
expected, PCSK9 protein levels in the livers of sgPcsk9
mice were substantially reduced compared to the mice
injected with PBS and sgRosa26 (Fig. 3d). The efficient
editing, PCSK9 reduction, and diminished serum cholesterol
indicate the successful delivery and activity of NmeCas9 at
the Pcsk9 locus.
SpyCas9 delivered by viral vectors is known to elicit
host immune responses [19, 53]. To investigate if the
mice injected with AAV8-sgRNA-hNmeCas9 generate
anti-NmeCas9 antibodies, we used sera from the treated
animals to perform IgG1 ELISA. Our results show that
NmeCas9 elicits a humoral response in these animals
(Additional file 1: Figure S4). Despite the presence of an
immune response, NmeCas9 delivered by rAAV is highly
functional in vivo, with no apparent signs of abnormal-
ities or liver damage (Additional file 1: Figure S5).
NmeCas9 is highly specific in vivo
A significant concern in therapeutic CRISPR/Cas9 gen-
ome editing is the possibility of off-target edits. We and
others have found that wild-type NmeCas9 is a naturally
high-accuracy genome editing platform in cultured mam-
malian cells [32] (Amrani et al., manuscript in revision).
To determine if NmeCas9 maintains its minimal
off-targeting profile in mouse cells and in vivo, we
screened for off-target sites in the mouse genome using
Fig. 3 AAV-delivery of NmeCas9 for in vivo genome editing. a Experimental outline of AAV8-sgRNA-hNmeCas9 vector tail-vein injections to target
Pcsk9 (sgPcsk9) and Rosa26 (sgRosa26) in C57Bl/6 mice. Mice were sacrificed at 14 (n = 1) or 50 days (n = 5) post injection and liver tissues were
harvested. Blood sera were collected at days 0, 25, and 50 post injection for cholesterol level measurement. b Serum cholesterol levels. p values
are calculated by unpaired t test. c Stacked histogram showing the percentage distribution of indels at Pcsk9 or Rosa26 in livers of mice, as
measured by targeted deep-sequencing analyses. Data are presented as mean ± SD from five mice per cohort. d A representative anti-PCSK9
western blot using total protein collected from day 50 mouse liver homogenates. A total of 2 ng of recombinant mouse PCSK9 (r-PCSK9) was
included as a mobility standard. The asterisk indicates a cross-reacting protein that is larger than the control recombinant protein
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genome-wide, unbiased identification of DSBs enabled by
sequencing (GUIDE-seq) [22]. Hepa1–6 cells were trans-
fected with sgPcsk9, sgRosa26, sgHpd1, and sgHpd2
all-in-one AAV-sgRNA-hNmeCas9 plasmids and the
resulting genomic DNA was subjected to GUIDE-seq ana-
lysis. Consistent with our previous observations in human
cells (Amrani et al., manuscript in revision), GUIDE-seq
revealed very few off-target (OT) sites in the mouse
genome. Four potential OT sites were identified for
sgPcsk9 and another six for sgRosa26. We were unable
to detect off-target edits with sgHpd1 and sgHpd2
(Fig. 4a), thus reinforcing our previous observation that
NmeCas9 is often intrinsically hyper-accurate (Amrani
et al., manuscript in revision).
Several of the putative OT sites for sgPcsk9 and sgRosa26
lack the NmeCas9 PAM preferences (N4GATT, N4GCTT,
N4GTTT, N4GACT, N4GATA, N4GTCT, and N4GACA)
(Fig. 4b) and may therefore represent background. To val-
idate these OT sites, we performed targeted deep sequen-
cing using genomic DNA from Hepa1–6 cells. By this
more sensitive readout, indels were undetectable above
background at all these OT sites except OT1 of Pcsk9,
which had an indel frequency < 2% (Fig. 4b). To validate
NmeCas9’s high fidelity in vivo, we measured indel
formation at these OT sites in liver genomic DNA from
the AAV8-NmeCas9-treated, sgPcsk9-targeted, and sgRo-
sa26-targeted mice. We found little or no detectable
off-target editing in mice liver sacrificed at 14 days at all
sites except sgPcsk9 OT1, which exhibited < 2% lesion effi-
ciency (Fig. 4c). More importantly, this level of OT editing
stayed below < 2% even after 50 days and also remained
either undetectable or very low for all other candidate OT
sites. These results suggested that extended (50 days) ex-
pression of NmeCas9 in vivo does not compromise its tar-
geting fidelity (Fig. 4c).
Discussion
All-in-one rAAV delivery of hNmeCas9
Compared to transcription activator-like effector nucle-
ases (TALENs) and Zinc-finger nucleases (ZFNs), Cas9s
are distinguished by their flexibility and versatility [1].
Such characteristics make them ideal for driving the field
of genome engineering forward. Over the past few years,
CRISPR-Cas9 has been used to enhance products in agri-
culture, food, and industry, in addition to the promising
applications in gene therapy and personalized medicine
[54]. Despite the diversity of Class 2 CRISPR systems that
have been described, only a handful of them have been
Fig. 4 GUIDE-seq genome-wide specificities of NmeCas9. a Number of GUIDE-seq reads for the on-target (OnT) and off-target (OT) sites. b
Targeted deep sequencing to measure the lesion rates at each of the OT sites in Hepa1–6 cells. The mismatches of each OT site with the OnT
protospacers is highlighted (blue). Data are presented as mean ± SD from three biological replicates. c Targeted deep sequencing to measure the
lesion rates at each of the OT sites using genomic DNA obtained from mice injected with all-in-one AAV8-sgRNA-hNmeCas9 sgPcsk9 and sgRosa26
and sacrificed at day 14 (D14) or day 50 (D50) post injection. Data are presented as mean ± SD
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developed and validated for genome editing in vivo. In this
study, we have shown that NmeCas9 is a compact,
high-fidelity Cas9 that can be considered for future in vivo
genome editing applications using all-in-one rAAV. Its
unique PAM enables editing at additional targets that are
inaccessible to the other two compact, all-in-one
rAAV-validated orthologs (SauCas9 and CjeCas9).
Therapeutic gene correction for hereditary Tyrosinemia
type 1 by metabolic pathway reprograming
Patients with mutations in the HPD gene are considered
to have Type III Tyrosinemia and exhibit high level of
tyrosine in blood, but otherwise appear to be largely
asymptomatic [55, 56]. HPD acts upstream of FAH in
the tyrosine catabolism pathway and Hpd disruption
ameliorates HT-I symptoms by preventing the toxic me-
tabolite build-up that results from loss of FAH. Struc-
tural analyses of HPD reveal that the catalytic domain of
the HPD enzyme is located at the C-terminus of the en-
zyme and encoded by exon 13 and 14 [57]. Thus, frame-
shift-inducing indels upstream of exon 13 should render the
enzyme inactive. We used this context to demonstrate that
Hpd inactivation by hydrodynamic injection of NmeCas9
plasmid is a viable approach to rescue HT-I mice. NmeCas9
can edit sites carrying several different PAMs (N4GATT
[consensus], N4GCTT, N4GTTT, N4GACT, N4GATA,
N4GTCT, and N4GACA) (Amrani et al., manuscript in revi-
sion). Our Hpd editing experiments confirmed one of the
variant PAMs in vivo with the sgHpd2 guide, which targets
a site with a N4GACT PAM.
Efficient, accurate NmeCas9 genome editing with rAAV
delivery
To achieve targeted delivery of NmeCas9 to various tis-
sues in vivo, rAAV vectors are a promising delivery plat-
form due to the compact size of NmeCas9 transgene,
which allows the delivery of NmeCas9 and its guide in an
all-in-one format. We have validated this approach for the
targeting of Pcsk9 and Rosa26 genes in adult mice, with ef-
ficient editing observed even at 14 days post injection. As
observed previously in cultured cells [32] (Amrani et al.,
manuscript in revision), NmeCas9 is intrinsically accurate,
even without the extensive engineering that was required
to reduce off-targeting by SpyCas9 [21–23]. We per-
formed side-by-side comparisons of NmeCas9 OT editing
in cultured cells and in vivo by targeted deep sequencing
and we found that off-targeting is minimal in both set-
tings. Editing at the sgPcsk9 OT1 site (within an unanno-
tated locus) was the highest detectable at ~ 2%. Despite
these promising results, more extensive and long-term
studies, including in larger animals, will be needed to fully
understand the long-term effects of Cas9 expression in tis-
sues, as well as the development of approaches that clear
viral vectors after editing is complete.
Conclusions
We demonstrate that NmeCas9 is amenable to in vivo gen-
ome editing using the highly desirable all-in-one rAAV plat-
form. With its unique PAM preferences and high fidelity,
this all-in-one AAV-sgRNA-hNeCas9 can be applied to a
range of genome editing purposes in vivo. We anticipate
that successful in vivo delivery of this accurate and effective
Cas9 can advance therapeutic editing in humans.
Methods
Construction of all-in-one AAV-sgRNA-hNMeCas9 plasmid
and rAAV vector production
The human-codon-optimized NmeCas9 gene under the
control of the U1a promoter and a sgRNA cassette
driven by the U6 promoter were cloned into an AAV2
plasmid backbone. The NmeCas9 ORF was flanked by
four nuclear localization signals – two on each terminus
– in addition to a triple-HA epitope tag. This plasmid is
available through Addgene (plasmid ID 112139). Oligo-
nucleotides with spacer sequences targeting Hpd, Pcsk9,
and Rosa26 were inserted into the sgRNA cassette by
ligation into a SapI cloning site (Additional file 2).
AAV vector production was performed at the Horae
Gene Therapy Center at the University of Massachusetts
Medical School. Briefly, plasmids were packaged in
AAV8 capsid by triple-plasmid transfection in HEK293
cells and purified by sedimentation as previously de-
scribed [58].
The off-target profiles of these spacers were predicted
computationally using the Bioconductor package CRISPR-
seek. Search parameters were adapted to NmeCas9 set-
tings as described previous (Amrani et al., manuscript in
revision): gRNA.size = 24, PAM= “NNNNGATT,” PAM.-
size = 8, RNA.PAM.pattern = “NNNNGNNN$,” weights =
c(0, 0, 0, 0, 0, 0, 0.014, 0, 0, 0.395, 0.317, 0, 0.389, 0.079,
0.445, 0.508, 0.613, 0.851, 0.732, 0.828, 0.615, 0.804, 0.685,
0.583), max.mismatch = 6, allowed.mismatch.PAM= 7,
topN = 10,000, min.score = 0.
Cell culture and transfection
Mouse Hepa1–6 hepatoma cells were cultured in DMEM
with 10% fetal bovine serum and 1% Penicillin/Strepto-
mycin (Gibco) in a 37 °C incubator with 5% CO2. Transi-
ent transfections of Hepa1–6 cells were performed using
Lipofectamine LTX. For transient transfection, approxi-
mately 1 × 105 cells per well were cultured in 24-well
plates 24 h before transfection. Each well was transfected
with 500-ng all-in-one AAV-sgRNA-hNmeCas9 plasmid,
using Lipofectamine LTX with Plus Reagent (Invitrogen)
according to the manufacturer’s protocol.
DNA isolation from cells and liver tissue
Genomic DNA isolation from cells was performed 72 h
post transfection using DNeasy Blood and Tissue kit
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(Qiagen) following the manufacturer’s protocol. Mice
were sacrificed and liver tissues were collected 10 days
post hydrodynamic injection or 14 and 50 days post
tail-vein rAAV injection. Genomic DNA was isolated
using DNeasy Blood and Tissue kit (Qiagen) according
to the manufacturer’s protocol.
GUIDE-seq
GUIDE-seq analysis was performed as previously described
[22]. Briefly, 7.5 pmol of annealed GUIDE-seq oligonucleo-
tides and 500 ng of all-in-one AAV-sgRNA-hNmeCas9
plasmids targeting Pcsk9, Rosa26, and Hpd were trans-
fected into 1 × 105 Hepa1–6 cells using Lipofectamine LTX
with Plus Reagent (Invitrogen). At 72 h post transfection,
genomic DNA was extracted using a DNeasy Blood and
Tissue kit (Qiagen) per manufacturer protocol. Library
preparations, deep sequencing, and reads analysis were
performed as previously described [59, 60]. The Biocon-
ductor package GUIDEseq was used for off-target analysis
as described previously using maximum allowed mismatch
of 10 nt between the guide and target DNA [59]. For read
alignment, mouse mm10 was used as a reference genome.
Indel analysis
TIDE primers were designed ~ 700 bp apart, with the
forward primer at ~ 200 bp upstream of the cleavage
site. A total of 50 ng of genomic DNA was used for PCR
amplification with High Fidelity 2X PCR Master Mix
(New England Biolabs). For TIDE analysis, 30 μL of a
PCR product was purified using QIAquick PCR Purifica-
tion Kit (Qiagen) and sent for Sanger sequencing using
the TIDE forward primer (Additional file 3). Indel values
were obtained using the TIDE web tool (https://tide-cal
culator.nki.nl/) as described previously [41].
Targeted deep-sequencing analysis was performed for
Hepa1–6 cells and mouse liver gDNA using a two-step
PCR amplification approach as described previously [60]
(Amrani et al., manuscript in revision). Briefly, in the first
PCR step, on-target or off-target locus-specific primers
were used to amplify the editing site using Phusion High Fi-
delity DNA Polymerase (New England Biolabs) with a 65 °
C annealing temperature. The primer ends contained se-
quences complementary to Illumina TruSeq adaptor se-
quences (Additional file 3). In the second-step PCR,
equimolar amounts of DNA were amplified with a univer-
sal forward primer and an indexed reverse primer using
Phusion High Fidelity DNA Polymerase (98 °C, 15 s; 61 °C,
25 s; 72 °C, 18 s; nine cycles) to ligate the TruSeq adaptors.
The resultant amplicons were separated in a 2.5% agarose
gel and the corresponding ~ 250-bp product bands were
extracted using Monarch DNA Gel Extraction Kit (New
England Biolabs).
The libraries were then sequenced on an Illumina
MiSeq in paired-end mode with a read length of 150 bp.
To analyze genome editing outcomes at genomic sites,
the command line utilities of CRISPResso were used
[61]. Input parameters were adjusted to filter low-quality
reads (−q 30 -s 20). Furthermore, the background was
determined using the control sample (no guide) and
subtracted from the experimental samples. The resulting
indel frequencies, sizes, and distributions were then plot-
ted using Graphpad PRISM.
Animals and liver tissue processing
For hydrodynamic injections, 2.5 mL of 30 μg of
endotoxin-free AAV-sgRNA-hNmeCas9 plasmid target-
ing Pcsk9 or 2.5 mL PBS was injected by tail vein into 9-
to 18-week-old female C57BL/6 mice. Mice were eutha-
nized 10 days later and liver tissue was harvested. For
the AAV8 vector injections, 12- to 16-week-old female
C57BL/6 mice were injected with 4 × 1011 genome cop-
ies per mouse via tail vein, using vectors targeting Pcsk9
or Rosa26. Mice were sacrificed 14 and 50 days after
vector administration and liver tissues were collected for
analysis.
For Hpd targeting, 2 mL PBS or 2 mL of 30 μg of
endotoxin-free AAV-sgRNA-hNmeCas9 plasmid was ad-
ministered into 15- to 21-week-old Type 1 Tyrosinemia Fah
knockout mice (Fahneo) via tail vein. The encoded sgRNAs
targeted sites in exon 8 (sgHpd1) or exon 11 (sgHpd2). The
HT1 homozygous mice with the Fahneo allele in a 129 back-
ground were kindly provided by Dr. Markus Grompe [50].
The HT1 mice were fed with 10 mg/L NTBC (2-(2-nitro-4--
trifluoromethylbenzoyl)-1,3-cyclohexanedione) (Sigma-Al-
drich, Cat. No. PHR1731-1G) in drinking water when
indicated. Both sexes were used in these experiments. Mice
were maintained on NTBC water for seven days post injec-
tion and then switched to normal water. Body weight was
monitored every 1–3 days. The PBS-injected control mice
were sacrificed when they became moribund after losing
20% of their body weight after removal from NTBC
treatment.
Mice were euthanized according to our protocol and
liver tissue was sliced and fragments stored at − 80 °C.
Some liver tissues were fixed in 4% formalin overnight, em-
bedded in paraffin, sectioned and stained with hematoxylin
and eosin (H&E).
Serum analysis
Blood (~ 200 μL) was drawn from the facial vein at 0,
25, and 50 days post vector administration. Serum was
isolated using a serum separator (BD, Cat. No. 365967)
and stored under − 80 °C until assay.
Serum cholesterol levels were measured by Infinity™
colorimetric endpoint assay (Thermo-Scientific) follow-
ing the manufacturer’s protocol. Briefly, serial dilutions
of Data-Cal™ Chemistry Calibrator were prepared in
PBS. In a 96-well plate, 2 μL of mice sera or calibrator
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dilution was mixed with 200 μL of Infinity™ cholesterol
liquid reagent, then incubated at 37 °C for 5 min. The
absorbance was measured at 500 nm using a BioTek
Synergy HT microplate reader.
Western blot
Liver tissue fractions were ground and resuspended in
150 μL of RIPA lysis buffer. Total protein content was
estimated by Pierce™ BCA Protein Assay Kit (Thermo--
Scientific) following the manufacturer’s protocol. A total
of 20 μg of protein from tissue or 2 ng of Recombinant
Mouse Proprotein Convertase 9/PCSK9 Protein (R&D
Systems, 9258-SE-020) were loaded onto a 4–20% Mini--
PROTEAN® TGX™ Precast Gel (Bio-Rad). The separated
bands were transferred onto PVDF membrane and
blocked with 5% Blocking-Grade Blocker solution
(Bio-Rad) for 2 h at room temperature. Membranes were
incubated with rabbit anti-GAPDH (Abcam ab9485,
1:2000) or goat anti-PCSK9 (R&D Systems AF3985, 1:400)
antibodies overnight at 4 °C. Membranes were washed five
times in TBST and incubated with horseradish peroxidase
(HRP)-conjugated goat anti-rabbit (Bio-Rad 1,706,515,
1:4000) and donkey anti-goat (R&D Systems HAF109,
1:2000) secondary antibodies for 2 h at room temperature.
The membranes were washed five times in TBST and vi-
sualized with Clarity™ western ECL substrate (Bio-Rad)
using an M35A X-OMAT Processor (Kodak).
Humoral immune response
Humoral IgG1 immune response to NmeCas9 was mea-
sured by ELISA (Bethyl; Mouse IgG1 ELISA Kit, E99–
105) following manufacturer’s protocol with a few modifi-
cations. Briefly, expression and three-step purification of
NmeCas9 and SpyCas9 was performed as previously de-
scribed [4]. A total of 0.5 μg of recombinant NmeCas9 or
SpyCas9 proteins suspended in 1× coating buffer (Bethyl)
were used to coat 96-well plates (Corning) and incubated
for 12 h at 4 °C with shaking. The wells were washed three
times while shaking for 5 min using 1× Wash Buffer.
Plates were blocked with 1× BSA Blocking Solution
(Bethyl) for 2 h at room temperature, then washed three
times. Serum samples were diluted 1:40 using PBS and
added to each well in duplicate. After incubating the sam-
ples at 4 °C for 5 h, the plates were washed 3× times for
5 min and 100 μL of biotinylated anti-mouse IgG1 anti-
body (Bethyl; 1: 100,000 in 1 x BSA Blocking Solution)
was added to each well. After incubating for 1 h at room
temperature, the plates were washed four times and
100 μL of TMB Substrate was added to each well. The
plates were allowed to develop in the dark for 20 min at
room temperature and 100 μL of ELISA Stop Solution
was then added per well. Following the development of
the yellow solution, absorbance was recorded at 450 nm
using a BioTek Synergy HT microplate reader.
Additional files
Additional file 1: Figure S1. Genome-wide computational prediction of
NmeCas9 off-target sites using CRISPRseek with the N4GN3 PAM. Search
parameters were set to identify sites with up to six mismatches to the
spacer sequence. The total number of detected off-target sites for each
protospacer is indicated. Figure S2. Stacked histogram showing the
percentage distribution of indels obtained by TIDE after AAV-sgRNA-
hNmeCas9 plasmids transfections in Hepa1–6. Error bars represent three
independent experiments. Data are presented as mean ± SD. Figure S3.
H&E staining from wild-type (Fah+/+) mouse, and HT-I mice (Fah−/−)
injected with PBS or AAV-sgRNA-hNmeCas9 plasmids sgHpd1 or sgHpd2.
Scale bar is 20 μm. Figure S4. Humoral IgG1 immune response to
NmeCas9 in vivo. Serum collected at day 50 post injection with all-in-one
AAV8-sgRNA-hNmeCas9 sgPcsk9 and sgRosa26. Serum antibodies reacted
against NmeCas9 protein (left) or SpyCas9 protein (right). Figure S5. H&E
staining from PBS, sgPcsk9, and sgRosa26 AAV8 injected mice. Scale bar is
20 μm. (PDF 713 kb)
Additional file 2: Nucleotide sequence of all-in-one AAV-sgRNA-
hNmeCas9 Plasmid. (PDF 59 kb)
Additional file 3: Contains Protospacer sequences, TIDE Primers
sequences, and Deep-sequencing Primers sequences. (PDF 69 kb)
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